Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Net Income (2022 - 2025)

Historic Net Income for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to -$10.8 million.

  • TriSalus Life Sciences' Net Income fell 35064.61% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.6 million, marking a year-over-year increase of 2877.86%. This contributed to the annual value of -$30.0 million for FY2024, which is 4938.77% up from last year.
  • Per TriSalus Life Sciences' latest filing, its Net Income stood at -$10.8 million for Q3 2025, which was down 35064.61% from -$8.3 million recorded in Q2 2025.
  • In the past 5 years, TriSalus Life Sciences' Net Income ranged from a high of $2.8 million in Q1 2022 and a low of -$35.6 million during Q4 2023
  • Its 4-year average for Net Income is -$9.6 million, with a median of -$8.3 million in 2025.
  • The largest annual percentage gain for TriSalus Life Sciences' Net Income in the last 5 years was 8239.22% (2023), contrasted with its biggest fall of 68560.77% (2023).
  • Over the past 4 years, TriSalus Life Sciences' Net Income (Quarter) stood at -$22.5 million in 2022, then plummeted by 58.1% to -$35.6 million in 2023, then soared by 71.64% to -$10.1 million in 2024, then fell by 6.95% to -$10.8 million in 2025.
  • Its last three reported values are -$10.8 million in Q3 2025, -$8.3 million for Q2 2025, and -$10.4 million during Q1 2025.